AustralieFrV1, PascalFrancis, Corpus, bibRecord, 004427

Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC) : A meta-analysis of individual data from 1764 patients

Identifieur interne : 004427 ( PascalFrancis/Corpus ); précédent : 004426; suivant : 004428

Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC) : A meta-analysis of individual data from 1764 patients

Auteurs : A. Auperin ; C. Le Pechoux ; J. P. Pignon ; C. Koning ; B. Jeremic ; G. Clamon ; L. Einhorn ; D. Ball ; M. G. Trovo ; H. J. M. Groen ; J. A. Bonner ; T. Le Chevalier ; R. Arriagada

Source :

Annals of oncology [ 0923-7534 ] ; 2006.

RBID : Pascal:06-0238910

Descripteurs français

Pascal (Inist)
- Chimiothérapie, Traitement, Homme, Stade avancé, Carcinome non petite cellule bronchopulmonaire, Cancer du poumon, Métaanalyse, Analyse donnée, Essai clinique, Revue systématique, Article synthèse.

English descriptors

KwdEn :
- Advanced stage, Chemotherapy, Clinical trial, Data analysis, Human, Lung cancer, Metaanalysis, Review, Systematic review, Treatment, non-small cell lung carcinoma.

Abstract

Background: Despite several randomised trials comparing radiotherapy alone with concomitant radio-chemotherapy in patients with locally advanced non-small cell lung cancer (NSCLC), it is not clear whether the addition of chemotherapy improves survival. Patients and methods: This meta-analysis was based on individual patient data from published and unpublished randomised trials which compared radiotherapy alone with the same radiotherapy combined with concomitant cisplatin- or carboplatin-based chemotherapy. Trials with accrual completed after 2000 were excluded. Trials were sought in electronic databases, clinical trial registries and by additional manual searches. The primary endpoint was overall survival analysed using the log-rank test stratified by trials. Results: There were twelve eligible trials that included a total of 1921 patients. The data from 3 trials were not available. Therefore, the analysis was based on 9 trials including 1764 patients. Median follow-up was 7.2 years. The hazard ratio of death among patients treated with radio-chemotherapy compared to radiotherapy alone was 0.89 (95% confidence interval, 0.81-0.98; P = 0.02) corresponding to an absolute benefit of chemotherapy of 4% at 2 years. There was some evidence of heterogeneity among trials and sensitivity analyses did not lead to consistent results. The combination of platin with etoposide seemed more effective than platin alone. Conclusions: Concomitant platin-based radio-chemotherapy may improve survival of patients with locally advanced NSCLC. However, the available data are insufficient to accurately define the size of such a potential treatment benefit and the optimal schedule of chemotherapy.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0923-7534`
A03		`1`		`@0 Ann. oncol.`
A05				`@2 17`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC) : A meta-analysis of individual data from 1764 patients`
A11	`01`	`1`		`@1 AUPERIN (A.)`
A11	`02`	`1`		`@1 LE PECHOUX (C.)`
A11	`03`	`1`		`@1 PIGNON (J. P.)`
A11	`04`	`1`		`@1 KONING (C.)`
A11	`05`	`1`		`@1 JEREMIC (B.)`
A11	`06`	`1`		`@1 CLAMON (G.)`
A11	`07`	`1`		`@1 EINHORN (L.)`
A11	`08`	`1`		`@1 BALL (D.)`
A11	`09`	`1`		`@1 TROVO (M. G.)`
A11	`10`	`1`		`@1 GROEN (H. J. M.)`
A11	`11`	`1`		`@1 BONNER (J. A.)`
A11	`12`	`1`		`@1 LE CHEVALIER (T.)`
A11	`13`	`1`		`@1 ARRIAGADA (R.)`
A14	`01`			`@1 Unit of Biostatistics and Epidemiology, Institut Gustave-Roussy @2 Villejuif @3 FRA @Z 1 aut. @Z 3 aut.`
A14	`02`			`@1 Unit of Radiation Oncology, Institut Gustave-Roussy @2 Villejuif @3 FRA @Z 2 aut. @Z 13 aut.`
A14	`03`			`@1 The Academic Medical Center @2 Amsterdam @3 NLD @Z 4 aut.`
A14	`04`			`@1 The University Hospital @2 Kragujevac, Serbia @3 SCG @Z 5 aut.`
A14	`05`			`@1 The University of Iowa Hospital @3 USA @Z 6 aut.`
A14	`06`			`@1 The Indiana Cancer Pavilion @3 USA @Z 7 aut.`
A14	`07`			`@1 Peter MacCallum Cancer Centre @3 AUS @Z 8 aut.`
A14	`08`			`@1 Centro di Riferimento Oncologico, National Cancer Institute @2 Aviano @3 ITA @Z 9 aut.`
A14	`09`			`@1 University Hospital Groningen @3 NLD @Z 10 aut.`
A14	`10`			`@1 University of Alabama @2 Birmingham @3 USA @Z 11 aut.`
A14	`11`			`@1 Unit of Medicine, Institut Gustave-Roussy @2 Villejuif @3 FRA @Z 12 aut.`
A14	`12`			`@1 The Faculté de Médecine Paris XI @3 FRA @Z 13 aut.`
A17	`01`	`1`		`@1 Meta-Analysis of Cisplatin/carboplatin based Concomitant Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group @3 INC`
A20				`@1 473-483`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 22429 @5 354000142755240180`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 43 ref.`
A47	`01`	`1`		`@0 06-0238910`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Annals of oncology`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Background: Despite several randomised trials comparing radiotherapy alone with concomitant radio-chemotherapy in patients with locally advanced non-small cell lung cancer (NSCLC), it is not clear whether the addition of chemotherapy improves survival. Patients and methods: This meta-analysis was based on individual patient data from published and unpublished randomised trials which compared radiotherapy alone with the same radiotherapy combined with concomitant cisplatin- or carboplatin-based chemotherapy. Trials with accrual completed after 2000 were excluded. Trials were sought in electronic databases, clinical trial registries and by additional manual searches. The primary endpoint was overall survival analysed using the log-rank test stratified by trials. Results: There were twelve eligible trials that included a total of 1921 patients. The data from 3 trials were not available. Therefore, the analysis was based on 9 trials including 1764 patients. Median follow-up was 7.2 years. The hazard ratio of death among patients treated with radio-chemotherapy compared to radiotherapy alone was 0.89 (95% confidence interval, 0.81-0.98; P = 0.02) corresponding to an absolute benefit of chemotherapy of 4% at 2 years. There was some evidence of heterogeneity among trials and sensitivity analyses did not lead to consistent results. The combination of platin with etoposide seemed more effective than platin alone. Conclusions: Concomitant platin-based radio-chemotherapy may improve survival of patients with locally advanced NSCLC. However, the available data are insufficient to accurately define the size of such a potential treatment benefit and the optimal schedule of chemotherapy.
C02	`01`	`X`		`@0 002B02R`
C02	`02`	`X`		`@0 002B11A`
C03	`01`	`X`	`FRE`	`@0 Chimiothérapie @5 01`
C03	`01`	`X`	`ENG`	`@0 Chemotherapy @5 01`
C03	`01`	`X`	`SPA`	`@0 Quimioterapia @5 01`
C03	`02`	`X`	`FRE`	`@0 Traitement @5 02`
C03	`02`	`X`	`ENG`	`@0 Treatment @5 02`
C03	`02`	`X`	`SPA`	`@0 Tratamiento @5 02`
C03	`03`	`X`	`FRE`	`@0 Homme @5 03`
C03	`03`	`X`	`ENG`	`@0 Human @5 03`
C03	`03`	`X`	`SPA`	`@0 Hombre @5 03`
C03	`04`	`X`	`FRE`	`@0 Stade avancé @5 04`
C03	`04`	`X`	`ENG`	`@0 Advanced stage @5 04`
C03	`04`	`X`	`SPA`	`@0 Estadio avanzado @5 04`
C03	`05`	`X`	`FRE`	`@0 Carcinome non petite cellule bronchopulmonaire @2 NM @5 05`
C03	`05`	`X`	`ENG`	`@0 non-small cell lung carcinoma @2 NM @5 05`
C03	`05`	`X`	`SPA`	`@0 Carcinoma no pequeňa célula bronchopulmonar @2 NM @5 05`
C03	`06`	`X`	`FRE`	`@0 Cancer du poumon @2 NM @5 06`
C03	`06`	`X`	`ENG`	`@0 Lung cancer @2 NM @5 06`
C03	`06`	`X`	`SPA`	`@0 Cáncer del pulmón @2 NM @5 06`
C03	`07`	`X`	`FRE`	`@0 Métaanalyse @5 07`
C03	`07`	`X`	`ENG`	`@0 Metaanalysis @5 07`
C03	`07`	`X`	`SPA`	`@0 Meta-análisis @5 07`
C03	`08`	`X`	`FRE`	`@0 Analyse donnée @5 08`
C03	`08`	`X`	`ENG`	`@0 Data analysis @5 08`
C03	`08`	`X`	`SPA`	`@0 Análisis datos @5 08`
C03	`09`	`X`	`FRE`	`@0 Essai clinique @5 09`
C03	`09`	`X`	`ENG`	`@0 Clinical trial @5 09`
C03	`09`	`X`	`SPA`	`@0 Ensayo clínico @5 09`
C03	`10`	`X`	`FRE`	`@0 Revue systématique @2 FM @5 10`
C03	`10`	`X`	`ENG`	`@0 Systematic review @2 FM @5 10`
C03	`10`	`X`	`SPA`	`@0 Revisión sistemática @2 FM @5 10`
C03	`11`	`X`	`FRE`	`@0 Article synthèse @5 11`
C03	`11`	`X`	`ENG`	`@0 Review @5 11`
C03	`11`	`X`	`SPA`	`@0 Artículo síntesis @5 11`
C07	`01`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Respiratory disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Bronche pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Bronchus disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Bronquio patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Poumon pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Lung disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Pulmón patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Tumeur maligne @5 40`
C07	`04`	`X`	`ENG`	`@0 Malignant tumor @5 40`
C07	`04`	`X`	`SPA`	`@0 Tumor maligno @5 40`
N21				`@1 149`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0238910 INIST
ET :	Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC) : A meta-analysis of individual data from 1764 patients
AU :	AUPERIN (A.); LE PECHOUX (C.); PIGNON (J. P.); KONING (C.); JEREMIC (B.); CLAMON (G.); EINHORN (L.); BALL (D.); TROVO (M. G.); GROEN (H. J. M.); BONNER (J. A.); LE CHEVALIER (T.); ARRIAGADA (R.)
AF :	Unit of Biostatistics and Epidemiology, Institut Gustave-Roussy/Villejuif/France (1 aut., 3 aut.); Unit of Radiation Oncology, Institut Gustave-Roussy/Villejuif/France (2 aut., 13 aut.); The Academic Medical Center/Amsterdam/Pays-Bas (4 aut.); The University Hospital/Kragujevac, Serbia/Serbie-et-Monténégro (5 aut.); The University of Iowa Hospital/Etats-Unis (6 aut.); The Indiana Cancer Pavilion/Etats-Unis (7 aut.); Peter MacCallum Cancer Centre/Australie (8 aut.); Centro di Riferimento Oncologico, National Cancer Institute/Aviano/Italie (9 aut.); University Hospital Groningen/Pays-Bas (10 aut.); University of Alabama/Birmingham/Etats-Unis (11 aut.); Unit of Medicine, Institut Gustave-Roussy/Villejuif/France (12 aut.); The Faculté de Médecine Paris XI/France (13 aut.)
DT :	Publication en série; Niveau analytique
SO :	Annals of oncology; ISSN 0923-7534; Royaume-Uni; Da. 2006; Vol. 17; No. 3; Pp. 473-483; Bibl. 43 ref.
LA :	Anglais
EA :	Background: Despite several randomised trials comparing radiotherapy alone with concomitant radio-chemotherapy in patients with locally advanced non-small cell lung cancer (NSCLC), it is not clear whether the addition of chemotherapy improves survival. Patients and methods: This meta-analysis was based on individual patient data from published and unpublished randomised trials which compared radiotherapy alone with the same radiotherapy combined with concomitant cisplatin- or carboplatin-based chemotherapy. Trials with accrual completed after 2000 were excluded. Trials were sought in electronic databases, clinical trial registries and by additional manual searches. The primary endpoint was overall survival analysed using the log-rank test stratified by trials. Results: There were twelve eligible trials that included a total of 1921 patients. The data from 3 trials were not available. Therefore, the analysis was based on 9 trials including 1764 patients. Median follow-up was 7.2 years. The hazard ratio of death among patients treated with radio-chemotherapy compared to radiotherapy alone was 0.89 (95% confidence interval, 0.81-0.98; P = 0.02) corresponding to an absolute benefit of chemotherapy of 4% at 2 years. There was some evidence of heterogeneity among trials and sensitivity analyses did not lead to consistent results. The combination of platin with etoposide seemed more effective than platin alone. Conclusions: Concomitant platin-based radio-chemotherapy may improve survival of patients with locally advanced NSCLC. However, the available data are insufficient to accurately define the size of such a potential treatment benefit and the optimal schedule of chemotherapy.
CC :	002B02R; 002B11A
FD :	Chimiothérapie; Traitement; Homme; Stade avancé; Carcinome non petite cellule bronchopulmonaire; Cancer du poumon; Métaanalyse; Analyse donnée; Essai clinique; Revue systématique; Article synthèse
FG :	Appareil respiratoire pathologie; Bronche pathologie; Poumon pathologie; Tumeur maligne
ED :	Chemotherapy; Treatment; Human; Advanced stage; non-small cell lung carcinoma; Lung cancer; Metaanalysis; Data analysis; Clinical trial; Systematic review; Review
EG :	Respiratory disease; Bronchus disease; Lung disease; Malignant tumor
SD :	Quimioterapia; Tratamiento; Hombre; Estadio avanzado; Carcinoma no pequeňa célula bronchopulmonar; Cáncer del pulmón; Meta-análisis; Análisis datos; Ensayo clínico; Revisión sistemática; Artículo síntesis
LO :	INIST-22429.354000142755240180
ID :	06-0238910

Links to Exploration step

Pascal:06-0238910

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC) : A meta-analysis of individual data from 1764 patients</title>
<author><name sortKey="Auperin, A" sort="Auperin, A" uniqKey="Auperin A" first="A." last="Auperin">A. Auperin</name>
<affiliation><inist:fA14 i1="01"><s1>Unit of Biostatistics and Epidemiology, Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Le Pechoux, C" sort="Le Pechoux, C" uniqKey="Le Pechoux C" first="C." last="Le Pechoux">C. Le Pechoux</name>
<affiliation><inist:fA14 i1="02"><s1>Unit of Radiation Oncology, Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pignon, J P" sort="Pignon, J P" uniqKey="Pignon J" first="J. P." last="Pignon">J. P. Pignon</name>
<affiliation><inist:fA14 i1="01"><s1>Unit of Biostatistics and Epidemiology, Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Koning, C" sort="Koning, C" uniqKey="Koning C" first="C." last="Koning">C. Koning</name>
<affiliation><inist:fA14 i1="03"><s1>The Academic Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jeremic, B" sort="Jeremic, B" uniqKey="Jeremic B" first="B." last="Jeremic">B. Jeremic</name>
<affiliation><inist:fA14 i1="04"><s1>The University Hospital</s1>
<s2>Kragujevac, Serbia</s2>
<s3>SCG</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Clamon, G" sort="Clamon, G" uniqKey="Clamon G" first="G." last="Clamon">G. Clamon</name>
<affiliation><inist:fA14 i1="05"><s1>The University of Iowa Hospital</s1>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Einhorn, L" sort="Einhorn, L" uniqKey="Einhorn L" first="L." last="Einhorn">L. Einhorn</name>
<affiliation><inist:fA14 i1="06"><s1>The Indiana Cancer Pavilion</s1>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ball, D" sort="Ball, D" uniqKey="Ball D" first="D." last="Ball">D. Ball</name>
<affiliation><inist:fA14 i1="07"><s1>Peter MacCallum Cancer Centre</s1>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Trovo, M G" sort="Trovo, M G" uniqKey="Trovo M" first="M. G." last="Trovo">M. G. Trovo</name>
<affiliation><inist:fA14 i1="08"><s1>Centro di Riferimento Oncologico, National Cancer Institute</s1>
<s2>Aviano</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Groen, H J M" sort="Groen, H J M" uniqKey="Groen H" first="H. J. M." last="Groen">H. J. M. Groen</name>
<affiliation><inist:fA14 i1="09"><s1>University Hospital Groningen</s1>
<s3>NLD</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonner, J A" sort="Bonner, J A" uniqKey="Bonner J" first="J. A." last="Bonner">J. A. Bonner</name>
<affiliation><inist:fA14 i1="10"><s1>University of Alabama</s1>
<s2>Birmingham</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Le Chevalier, T" sort="Le Chevalier, T" uniqKey="Le Chevalier T" first="T." last="Le Chevalier">T. Le Chevalier</name>
<affiliation><inist:fA14 i1="11"><s1>Unit of Medicine, Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Arriagada, R" sort="Arriagada, R" uniqKey="Arriagada R" first="R." last="Arriagada">R. Arriagada</name>
<affiliation><inist:fA14 i1="02"><s1>Unit of Radiation Oncology, Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="12"><s1>The Faculté de Médecine Paris XI</s1>
<s3>FRA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0238910</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0238910 INIST</idno>
<idno type="RBID">Pascal:06-0238910</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">004427</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC) : A meta-analysis of individual data from 1764 patients</title>
<author><name sortKey="Auperin, A" sort="Auperin, A" uniqKey="Auperin A" first="A." last="Auperin">A. Auperin</name>
<affiliation><inist:fA14 i1="01"><s1>Unit of Biostatistics and Epidemiology, Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Le Pechoux, C" sort="Le Pechoux, C" uniqKey="Le Pechoux C" first="C." last="Le Pechoux">C. Le Pechoux</name>
<affiliation><inist:fA14 i1="02"><s1>Unit of Radiation Oncology, Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pignon, J P" sort="Pignon, J P" uniqKey="Pignon J" first="J. P." last="Pignon">J. P. Pignon</name>
<affiliation><inist:fA14 i1="01"><s1>Unit of Biostatistics and Epidemiology, Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Koning, C" sort="Koning, C" uniqKey="Koning C" first="C." last="Koning">C. Koning</name>
<affiliation><inist:fA14 i1="03"><s1>The Academic Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jeremic, B" sort="Jeremic, B" uniqKey="Jeremic B" first="B." last="Jeremic">B. Jeremic</name>
<affiliation><inist:fA14 i1="04"><s1>The University Hospital</s1>
<s2>Kragujevac, Serbia</s2>
<s3>SCG</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Clamon, G" sort="Clamon, G" uniqKey="Clamon G" first="G." last="Clamon">G. Clamon</name>
<affiliation><inist:fA14 i1="05"><s1>The University of Iowa Hospital</s1>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Einhorn, L" sort="Einhorn, L" uniqKey="Einhorn L" first="L." last="Einhorn">L. Einhorn</name>
<affiliation><inist:fA14 i1="06"><s1>The Indiana Cancer Pavilion</s1>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ball, D" sort="Ball, D" uniqKey="Ball D" first="D." last="Ball">D. Ball</name>
<affiliation><inist:fA14 i1="07"><s1>Peter MacCallum Cancer Centre</s1>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Trovo, M G" sort="Trovo, M G" uniqKey="Trovo M" first="M. G." last="Trovo">M. G. Trovo</name>
<affiliation><inist:fA14 i1="08"><s1>Centro di Riferimento Oncologico, National Cancer Institute</s1>
<s2>Aviano</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Groen, H J M" sort="Groen, H J M" uniqKey="Groen H" first="H. J. M." last="Groen">H. J. M. Groen</name>
<affiliation><inist:fA14 i1="09"><s1>University Hospital Groningen</s1>
<s3>NLD</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonner, J A" sort="Bonner, J A" uniqKey="Bonner J" first="J. A." last="Bonner">J. A. Bonner</name>
<affiliation><inist:fA14 i1="10"><s1>University of Alabama</s1>
<s2>Birmingham</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Le Chevalier, T" sort="Le Chevalier, T" uniqKey="Le Chevalier T" first="T." last="Le Chevalier">T. Le Chevalier</name>
<affiliation><inist:fA14 i1="11"><s1>Unit of Medicine, Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Arriagada, R" sort="Arriagada, R" uniqKey="Arriagada R" first="R." last="Arriagada">R. Arriagada</name>
<affiliation><inist:fA14 i1="02"><s1>Unit of Radiation Oncology, Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="12"><s1>The Faculté de Médecine Paris XI</s1>
<s3>FRA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term>
<term>Chemotherapy</term>
<term>Clinical trial</term>
<term>Data analysis</term>
<term>Human</term>
<term>Lung cancer</term>
<term>Metaanalysis</term>
<term>Review</term>
<term>Systematic review</term>
<term>Treatment</term>
<term>non-small cell lung carcinoma</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Stade avancé</term>
<term>Carcinome non petite cellule bronchopulmonaire</term>
<term>Cancer du poumon</term>
<term>Métaanalyse</term>
<term>Analyse donnée</term>
<term>Essai clinique</term>
<term>Revue systématique</term>
<term>Article synthèse</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Despite several randomised trials comparing radiotherapy alone with concomitant radio-chemotherapy in patients with locally advanced non-small cell lung cancer (NSCLC), it is not clear whether the addition of chemotherapy improves survival. Patients and methods: This meta-analysis was based on individual patient data from published and unpublished randomised trials which compared radiotherapy alone with the same radiotherapy combined with concomitant cisplatin- or carboplatin-based chemotherapy. Trials with accrual completed after 2000 were excluded. Trials were sought in electronic databases, clinical trial registries and by additional manual searches. The primary endpoint was overall survival analysed using the log-rank test stratified by trials. Results: There were twelve eligible trials that included a total of 1921 patients. The data from 3 trials were not available. Therefore, the analysis was based on 9 trials including 1764 patients. Median follow-up was 7.2 years. The hazard ratio of death among patients treated with radio-chemotherapy compared to radiotherapy alone was 0.89 (95% confidence interval, 0.81-0.98; P = 0.02) corresponding to an absolute benefit of chemotherapy of 4% at 2 years. There was some evidence of heterogeneity among trials and sensitivity analyses did not lead to consistent results. The combination of platin with etoposide seemed more effective than platin alone. Conclusions: Concomitant platin-based radio-chemotherapy may improve survival of patients with locally advanced NSCLC. However, the available data are insufficient to accurately define the size of such a potential treatment benefit and the optimal schedule of chemotherapy.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0923-7534</s0>
</fA01>
<fA03 i2="1"><s0>Ann. oncol.</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC) : A meta-analysis of individual data from 1764 patients</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>AUPERIN (A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LE PECHOUX (C.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PIGNON (J. P.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>KONING (C.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>JEREMIC (B.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CLAMON (G.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>EINHORN (L.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BALL (D.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>TROVO (M. G.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>GROEN (H. J. M.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>BONNER (J. A.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>LE CHEVALIER (T.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>ARRIAGADA (R.)</s1>
</fA11>
<fA14 i1="01"><s1>Unit of Biostatistics and Epidemiology, Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Unit of Radiation Oncology, Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>The Academic Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>The University Hospital</s1>
<s2>Kragujevac, Serbia</s2>
<s3>SCG</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>The University of Iowa Hospital</s1>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>The Indiana Cancer Pavilion</s1>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Peter MacCallum Cancer Centre</s1>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Centro di Riferimento Oncologico, National Cancer Institute</s1>
<s2>Aviano</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>University Hospital Groningen</s1>
<s3>NLD</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>University of Alabama</s1>
<s2>Birmingham</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Unit of Medicine, Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>The Faculté de Médecine Paris XI</s1>
<s3>FRA</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>Meta-Analysis of Cisplatin/carboplatin based Concomitant Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>473-483</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>22429</s2>
<s5>354000142755240180</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>43 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0238910</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Annals of oncology</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Despite several randomised trials comparing radiotherapy alone with concomitant radio-chemotherapy in patients with locally advanced non-small cell lung cancer (NSCLC), it is not clear whether the addition of chemotherapy improves survival. Patients and methods: This meta-analysis was based on individual patient data from published and unpublished randomised trials which compared radiotherapy alone with the same radiotherapy combined with concomitant cisplatin- or carboplatin-based chemotherapy. Trials with accrual completed after 2000 were excluded. Trials were sought in electronic databases, clinical trial registries and by additional manual searches. The primary endpoint was overall survival analysed using the log-rank test stratified by trials. Results: There were twelve eligible trials that included a total of 1921 patients. The data from 3 trials were not available. Therefore, the analysis was based on 9 trials including 1764 patients. Median follow-up was 7.2 years. The hazard ratio of death among patients treated with radio-chemotherapy compared to radiotherapy alone was 0.89 (95% confidence interval, 0.81-0.98; P = 0.02) corresponding to an absolute benefit of chemotherapy of 4% at 2 years. There was some evidence of heterogeneity among trials and sensitivity analyses did not lead to consistent results. The combination of platin with etoposide seemed more effective than platin alone. Conclusions: Concomitant platin-based radio-chemotherapy may improve survival of patients with locally advanced NSCLC. However, the available data are insufficient to accurately define the size of such a potential treatment benefit and the optimal schedule of chemotherapy.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02R</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B11A</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Traitement</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Treatment</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Stade avancé</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Advanced stage</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Estadio avanzado</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Carcinome non petite cellule bronchopulmonaire</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>non-small cell lung carcinoma</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Carcinoma no pequeňa célula bronchopulmonar</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Cancer du poumon</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Lung cancer</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Cáncer del pulmón</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Métaanalyse</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Metaanalysis</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Meta-análisis</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Analyse donnée</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Data analysis</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Análisis datos</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Revue systématique</s0>
<s2>FM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Systematic review</s0>
<s2>FM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Revisión sistemática</s0>
<s2>FM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Review</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Bronche pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Bronchus disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Bronquio patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>40</s5>
</fC07>
<fN21><s1>149</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0238910 INIST</NO>
<ET>Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC) : A meta-analysis of individual data from 1764 patients</ET>
<AU>AUPERIN (A.); LE PECHOUX (C.); PIGNON (J. P.); KONING (C.); JEREMIC (B.); CLAMON (G.); EINHORN (L.); BALL (D.); TROVO (M. G.); GROEN (H. J. M.); BONNER (J. A.); LE CHEVALIER (T.); ARRIAGADA (R.)</AU>
<AF>Unit of Biostatistics and Epidemiology, Institut Gustave-Roussy/Villejuif/France (1 aut., 3 aut.); Unit of Radiation Oncology, Institut Gustave-Roussy/Villejuif/France (2 aut., 13 aut.); The Academic Medical Center/Amsterdam/Pays-Bas (4 aut.); The University Hospital/Kragujevac, Serbia/Serbie-et-Monténégro (5 aut.); The University of Iowa Hospital/Etats-Unis (6 aut.); The Indiana Cancer Pavilion/Etats-Unis (7 aut.); Peter MacCallum Cancer Centre/Australie (8 aut.); Centro di Riferimento Oncologico, National Cancer Institute/Aviano/Italie (9 aut.); University Hospital Groningen/Pays-Bas (10 aut.); University of Alabama/Birmingham/Etats-Unis (11 aut.); Unit of Medicine, Institut Gustave-Roussy/Villejuif/France (12 aut.); The Faculté de Médecine Paris XI/France (13 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Annals of oncology; ISSN 0923-7534; Royaume-Uni; Da. 2006; Vol. 17; No. 3; Pp. 473-483; Bibl. 43 ref.</SO>
<LA>Anglais</LA>
<EA>Background: Despite several randomised trials comparing radiotherapy alone with concomitant radio-chemotherapy in patients with locally advanced non-small cell lung cancer (NSCLC), it is not clear whether the addition of chemotherapy improves survival. Patients and methods: This meta-analysis was based on individual patient data from published and unpublished randomised trials which compared radiotherapy alone with the same radiotherapy combined with concomitant cisplatin- or carboplatin-based chemotherapy. Trials with accrual completed after 2000 were excluded. Trials were sought in electronic databases, clinical trial registries and by additional manual searches. The primary endpoint was overall survival analysed using the log-rank test stratified by trials. Results: There were twelve eligible trials that included a total of 1921 patients. The data from 3 trials were not available. Therefore, the analysis was based on 9 trials including 1764 patients. Median follow-up was 7.2 years. The hazard ratio of death among patients treated with radio-chemotherapy compared to radiotherapy alone was 0.89 (95% confidence interval, 0.81-0.98; P = 0.02) corresponding to an absolute benefit of chemotherapy of 4% at 2 years. There was some evidence of heterogeneity among trials and sensitivity analyses did not lead to consistent results. The combination of platin with etoposide seemed more effective than platin alone. Conclusions: Concomitant platin-based radio-chemotherapy may improve survival of patients with locally advanced NSCLC. However, the available data are insufficient to accurately define the size of such a potential treatment benefit and the optimal schedule of chemotherapy.</EA>
<CC>002B02R; 002B11A</CC>
<FD>Chimiothérapie; Traitement; Homme; Stade avancé; Carcinome non petite cellule bronchopulmonaire; Cancer du poumon; Métaanalyse; Analyse donnée; Essai clinique; Revue systématique; Article synthèse</FD>
<FG>Appareil respiratoire pathologie; Bronche pathologie; Poumon pathologie; Tumeur maligne</FG>
<ED>Chemotherapy; Treatment; Human; Advanced stage; non-small cell lung carcinoma; Lung cancer; Metaanalysis; Data analysis; Clinical trial; Systematic review; Review</ED>
<EG>Respiratory disease; Bronchus disease; Lung disease; Malignant tumor</EG>
<SD>Quimioterapia; Tratamiento; Hombre; Estadio avanzado; Carcinoma no pequeňa célula bronchopulmonar; Cáncer del pulmón; Meta-análisis; Análisis datos; Ensayo clínico; Revisión sistemática; Artículo síntesis</SD>
<LO>INIST-22429.354000142755240180</LO>
<ID>06-0238910</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004427 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 004427 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0238910
   |texte=   Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC) : A meta-analysis of individual data from 1764 patients
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC) : A meta-analysis of individual data from 1764 patients

Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC) : A meta-analysis of individual data from 1764 patients

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri